TG Therapeutics Announces Pharmacokinetic, Pharmacodynamic, Safety, And Tolerability Data From Phase 1 Clinical Trial Evaluating Subcutaneous Formulation Of Ublituximab As Compared To IV BRIUMVI

Tg Therapeutics

Tg Therapeutics

TGTX

0.00

Pharmacokinetic and pharmacodynamic data support quarterly subcutaneous BRIUMVI dosing regimen currently under evaluation in fully enrolled Phase 3 trial; Top-line Phase 3 data expected year-end 2026 or early 2027 

Novel Investigational high concentration subcutaneous formulation of BRIUMVI was well-tolerated with no new safety signals observed

NEW YORK, June 03, 2026 (GLOBE NEWSWIRE) -- TG Therapeutics, Inc. (NASDAQ:TGTX) (the "Company" or "TG Therapeutics"), today announced positive pharmacokinetic (PK), pharmacodynamic (PD), safety, and tolerability data from its Phase 1 clinical trial evaluating subcutaneous formulation of ublituximab (the active agent in BRIUMVI®) as compared to IV BRIUMVI.

This page is machine-translated. Sahm tries to improve but does not guarantee the accuracy and reliability of the translation, and will not be liable for any loss or damage caused by any inaccuracy or omission of the translation. *Disclaimer: The above content only represents the author's personal position and opinion and does not represent any position of Sahm Capital Financial Company and Sahm cannot confirm the authenticity, accuracy, and originality of the above content. Investors should consider the risks of investment products in light of their circumstances before making any investment decisions. When necessary, please consult a professional investment advisor. Sahm does not provide any investment advice, nor does it make any commitments and guarantees.